Hemo Organic: 34 Lakh Shares Issued at ₹12.50 (2026)

What Hemo Organic disclosed

Hemo Organic Limited has reported a major change in its shareholding structure after converting convertible warrants into equity. The company said it allotted 34,00,000 fully paid-up equity shares following the conversion of an equal number of warrants. The allotment was approved by the Board at a meeting held on Friday, September 25, 2026. The issue price for conversion was ₹12.50 per share, including a ₹2.50 premium, with a face value of ₹10 per share. As per the disclosure, this allotment significantly expanded the company’s paid-up equity share capital.

Investors: Vacro and Qmin enter as shareholders

The preferential allotment on warrant conversion was executed in favour of two non-promoter corporate entities: Vacro Enterprises Private Limited and Qmin Realities Private Limited. Each entity was allotted 17,00,000 equity shares upon conversion of its respective 17,00,000 warrants. The company stated that neither Vacro nor Qmin held any equity shares in Hemo Organic prior to this issuance. After conversion, both entities became sizeable shareholders in the company. The company also received a specific disclosure from Vacro Enterprises Private Limited regarding its acquisition.

Stake created: 24.76% voting capital each

Following the issuance, each allottee holds 17,00,000 equity shares, translating into a 24.76% stake in the post-issue structure for Vacro and an identical 24.76% for Qmin. The disclosure describes this as a share of the company’s total voting capital after the allotment. In other words, the allotment introduced two large non-promoter shareholders at the same time and at the same economic terms. The company has treated this issuance as part of its regulatory disclosures under listing norms. The equity shares issued will rank pari-passu with existing shares, as stated by the company.

Capital expansion: equity base nearly doubled

Hemo Organic disclosed that its total equity share capital increased from 34,65,900 shares to 68,65,900 shares after the allotment. This change means the equity base almost doubled in terms of the number of shares outstanding. The company’s paid-up equity share capital value also increased in line with the face value, moving from ₹3,46,59,000 to ₹6,86,59,000. The face value per share remains ₹10, so the paid-up capital change is consistent with the increase in total shares. The disclosure positions the allotment as a significant step in changing the company’s post-issue capital structure.

Proceeds: ₹3.1875 crore received on conversion

At ₹12.50 per share for 34,00,000 shares, the proceeds indicated in the text work out to ₹3.1875 crore (₹3,18,75,000). The disclosure also refers to the amount received in two tranches. Another regulatory update cited in the provided text mentions that the Board approved receipt of a “second tranche” consideration amounting to ₹2.7625 crore from allottees in the Non-Promoter category for convertible warrants. The annexure details referenced include Vacro Enterprises Private Limited and Qmin Realities Private Limited. Separately, the text summarises the total as about ₹3.19 crore received from Vacro and Qmin via warrant conversion, consistent with the computed total.

Listing process: exchange approval to be sought

Hemo Organic said it will apply to the stock exchange for listing and trading approval for the newly allotted equity shares in due course. This is a standard step after allotment of new shares, enabling the new equity to be admitted for trading. The company’s disclosure also reiterates that the new shares will have the same rights as existing shares. While the timeline for exchange approvals was not specified in the provided text, the company confirmed its intention to complete the process. Investors typically track this step closely because it determines when newly issued shares become tradable.

Next trigger: October 3 board meeting on fundraise

Separately, Hemo Organic has scheduled a board meeting for Saturday, October 3, 2026 to consider raising funds in one or more tranches. The company said the fundraising could be done through the issue of equity shares and or convertible securities, including convertible warrants. The modes mentioned in the disclosure include preferential allotment and a qualified institutions placement (QIP), subject to statutory and regulatory approvals. The scheduled meeting comes soon after the company completed the 34 lakh share allotment on warrant conversion. The disclosure, however, does not specify the size or pricing of any fresh issuance that may be considered.

Business snapshot: white coal production in India

The provided text states that Hemo Organic is currently engaged in the production and sale of white coal in India. Beyond this business description, the excerpt does not provide additional operating or financial details, such as revenue, profitability, or capacity. Still, the capital-raising activity and the warrant conversion indicate active corporate actions around its equity base. For shareholders, such disclosures matter because they directly affect ownership percentages and can influence free float and market liquidity. Any further fundraise, if approved, could lead to additional changes in the capital structure.

Key facts table

Stock reference shared in the text

The provided text also includes a price reference stating Hemo Organic’s share price as ₹20.84 on BSE as of September 21, 2026 (12:10 PM). It also shows NSE ₹0.00 in the same line, as presented in the excerpt. The disclosure does not explain why the NSE value appears as zero, so it should be read strictly as a data point included in the provided text. No percentage movement or volume details were provided alongside this price reference.

Why this matters for shareholders

The conversion-led allotment is material because it introduced two new non-promoter shareholders with meaningful post-issue stakes. It also nearly doubled the company’s outstanding shares, which is a direct dilution event for existing shareholders in percentage terms. At the same time, the company is preparing to review additional fundraising options at its October 3 board meeting, which could potentially result in further issuance depending on approvals and final terms. The disclosures highlight that the company is actively using capital market instruments like warrants and preferential allotments, and it has also kept a QIP option open, subject to approvals.

Conclusion

Hemo Organic’s disclosures show a completed 34 lakh share allotment on warrant conversion at ₹12.50, bringing in about ₹3.1875 crore and lifting its equity base to 68.65 lakh shares. Vacro Enterprises and Qmin Realities now hold 24.76% each in the post-issue shareholding structure. The next immediate milestone is the October 3, 2026 board meeting, where the company will consider whether to raise additional funds through equity and or convertible securities, including routes such as preferential allotment or a QIP, subject to approvals.